Endothelial PAI-1 (Plasminogen Activator Inhibitor-1) Blocks the Intrinsic Pathway of Coagulation, Inducing the Clearance and Degradation of FXIa (Activated Factor XI).
endothelium
fibrin
kallikrein
platelet activation
thrombin
Journal
Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
entrez:
27
6
2019
pubmed:
27
6
2019
medline:
29
2
2020
Statut:
ppublish
Résumé
Objective- Activation of coagulation FXI (factor XI) by FXIIa (activated factor XII) is a prothrombotic process. The endothelium is known to play an antithrombotic role by limiting thrombin generation and platelet activation. It is unknown whether the antithrombotic role of the endothelium includes sequestration of FXIa (activated factor XI) activity. This study aims to determine the role of endothelial cells (ECs) in the regulation of the intrinsic pathway of coagulation. Approach and Results- Using a chromogenic assay, we observed that human umbilical veins ECs selectively blocked FXIa yet supported kallikrein and FXIIa activity. Western blotting and mass spectrometry analyses revealed that FXIa formed a complex with endothelial PAI-1 (plasminogen activator inhibitor-1). Blocking endothelial PAI-1 increased the cleavage of a chromogenic substrate by FXIa and the capacity of FXIa to promote fibrin formation in plasma. Western blot and immunofluorescence analyses showed that FXIa-PAI-1 complexes were either released into the media or trafficked to the early and late endosomes and lysosomes of ECs. When baboons were challenged with Staphylococcus aureus to induce a prothrombotic phenotype, an increase in circulating FXIa-PAI-1 complex levels was detected by ELISA within 2 to 8 hours postchallenge. Conclusions- PAI-1 forms a complex with FXIa on ECs, blocking its activity and inducing the clearance and degradation of FXIa. Circulating FXIa-PAI-1 complexes were detected in a baboon model of S. aureus sepsis. Although ECs support kallikrein and FXIIa activity, inhibition of FXIa by ECs may promote the clearance of intravascular FXIa. Visual Overview- An online visual overview is available for this article.
Identifiants
pubmed: 31242030
doi: 10.1161/ATVBAHA.119.312619
pmc: PMC6597189
mid: NIHMS1529314
doi:
Substances chimiques
Plasminogen Activator Inhibitor 1
0
Factor XIa
EC 3.4.21.27
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1390-1401Subventions
Organisme : NIH HHS
ID : P51 OD011092
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY010572
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL047014
Pays : United States
Organisme : NIH HHS
ID : S10 OD012246
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL101972
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM116184
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL140025
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA069533
Pays : United States
Références
J Cell Biol. 1991 Dec;115(6):1773-81
pubmed: 1721912
Blood Adv. 2019 Feb 26;3(4):658-669
pubmed: 30808684
J Thromb Haemost. 2013 Dec;11(12):2118-27
pubmed: 24152424
J Thromb Haemost. 2018 Sep;16(9):1674-1685
pubmed: 29920929
N Engl J Med. 2000 Mar 9;342(10):696-701
pubmed: 10706899
Blood. 2006 Dec 15;108(13):4045-51
pubmed: 16931632
Science. 1987 Aug 14;237(4816):777-9
pubmed: 3649921
Immunobiology. 1998 Aug;199(2):377-88
pubmed: 9777421
Blood. 2009 Jul 9;114(2):452-8
pubmed: 19351955
J Thromb Haemost. 2013 Jul;11(7):1341-52
pubmed: 23659638
J Biol Chem. 2002 Aug 9;277(32):28498-503
pubmed: 12029092
Am J Pathol. 2007 Sep;171(3):1066-77
pubmed: 17640967
Biochim Biophys Acta. 1984 Aug 28;789(1):37-43
pubmed: 6432051
Am J Clin Pathol. 2006 Sep;126(3):411-5
pubmed: 16880142
Thromb Haemost. 2001 Mar;85(3):544-51
pubmed: 11307829
Blood. 2012 Mar 15;119(11):2452-7
pubmed: 22234688
Blood. 2010 Nov 11;116(19):3981-9
pubmed: 20634381
J Clin Invest. 2008 Sep;118(9):3208-18
pubmed: 18725990
Thromb Res. 2016 May;141 Suppl 2:S8-S11
pubmed: 27207433
J Exp Med. 2012 Apr 9;209(4):819-35
pubmed: 22451716
J Clin Invest. 1955 Apr;34(4):602-13
pubmed: 14367514
Blood. 1997 Jul 1;90(1):204-8
pubmed: 9207454
Cell Mol Life Sci. 2004 Feb;61(3):301-25
pubmed: 14770295
Thromb Haemost. 1981 Aug 28;46(2):504-6
pubmed: 7302889
Biochemistry. 1997 Jan 14;36(2):412-20
pubmed: 9003194
PLoS One. 2016 Apr 05;11(4):e0152968
pubmed: 27046148
J Biol Chem. 1996 May 31;271(22):12913-8
pubmed: 8662679
Methods Mol Biol. 2012;788:91-100
pubmed: 22130702
J Biol Chem. 1989 Jul 15;264(20):11738-43
pubmed: 2787318
J Ocul Biol Dis Infor. 2009 Dec 12;2(4):223-234
pubmed: 20157357
J Biol Chem. 2000 Dec 1;275(48):37340-6
pubmed: 10973954
J Biol Chem. 1992 Oct 5;267(28):19833-9
pubmed: 1400299
Blood. 1995 Aug 1;86(3):1056-61
pubmed: 7620159
PLoS One. 2016 Oct 20;11(10):e0165172
pubmed: 27764259
Blood. 2001 Apr 15;97(8):2342-50
pubmed: 11290596
Front Med (Lausanne). 2017 Dec 20;4:232
pubmed: 29326937
J Clin Invest. 1984 Oct;74(4):1465-72
pubmed: 6434594
Blood. 1988 Aug;72(2):616-20
pubmed: 3135862
Curr Drug Targets. 2011 Nov;12(12):1782-9
pubmed: 21707474
J Am Soc Mass Spectrom. 2015 Nov;26(11):1865-74
pubmed: 26115965
Biochem Biophys Res Commun. 2008 Jul 11;371(4):787-92
pubmed: 18471992
J Thromb Haemost. 2016 Mar;14(3):427-37
pubmed: 26707513
Blood. 1997 Nov 15;90(10):3819-43
pubmed: 9354649
J Thromb Haemost. 2010 Jul;8(7):1532-9
pubmed: 20456758
J Biol Chem. 2002 Oct 11;277(41):38462-7
pubmed: 12167623
Immunity. 2011 Feb 25;34(2):258-68
pubmed: 21349432
J Thromb Haemost. 2009 Jul;7 Suppl 1:84-7
pubmed: 19630775
J Biol Chem. 2003 Nov 7;278(45):43983-90
pubmed: 12944405
Blood. 2015 Feb 26;125(9):1488-96
pubmed: 25587039
Blood. 1991 Sep 1;78(5):1254-61
pubmed: 1715220
J Biol Chem. 1989 Oct 25;264(30):18173-9
pubmed: 2478540
Chin Med Sci J. 2002 Mar;17(1):36-9
pubmed: 12894883